{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:42:27Z","timestamp":1784421747089,"version":"3.55.0"},"reference-count":47,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the pharmacology, clinical efficacy, safety, dosing, administration, and clinical implications of talquetamab-tgvs, a novel bispecific antibody, in the treatment of relapsed or refractory (R\/R) multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A comprehensive English-language literature search of PubMed and Clinicaltrials.gov from January 2000 to May 2024 was conducted using the terms talquetamab, Talvey, JNJ-64407564, and \u201cMultiple Myeloma.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Relevant clinical trials, guidelines, and prescribing information were systematically reviewed and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Talquetamab-tgvs received accelerated approval from the United States Food and Drug Administration based on results from the pivotal phase I\/II MonumenTAL-1 clinical trial, which demonstrated an overall response rate of nearly 74% in key cohorts. The median progression-free survival was 7.5 months in the 0.4 mg\/kg weekly dosing cohort and 11.9 months in the 0.8 mg\/kg biweekly dosing cohort. Treatment-related adverse events (AEs) included cytokine release syndrome, skin- and nail-related AEs, dysgeusia, infections, and immune effector cell-associated neurotoxicity syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>As a first-in-class anti-GPRC5D T-cell-redirecting bispecific antibody, talquetamab-tgvs represents a compelling treatment option for patients with R\/R MM who have received at least 4 prior lines of therapy. No head-to-head clinical trials have been conducted comparing talquetamab-tgvs to other T-cell-redirecting therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>While talquetamab-tgvs showed significant efficacy in the pivotal MonumenTAL-1 trial, long-term safety and efficacy data are needed. Additional clinical trials are necessary to establish the optimal timing, sequencing, patient population, and overall role of talquetamab-tgvs in the rapidly evolving treatment landscape of R\/R MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241271192","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:18:35Z","timestamp":1724807915000},"page":"350-363","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3899-0010","authenticated-orcid":false,"given":"Jacob","family":"Shaver","sequence":"first","affiliation":[{"name":"College of Pharmacy, Union University, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2741-0549","authenticated-orcid":false,"given":"Daniel","family":"Horton","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Union University, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Union University, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"bibr1-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"bibr2-10600280241271192","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"bibr3-10600280241271192","unstructured":"International Myeloma Foundation. Frontline therapy. Accessed May 7, 2024. https:\/\/www.myeloma.org\/frontline-treatment-options"},{"key":"bibr4-10600280241271192","unstructured":"National Comprehensive Cancer Network. Multiple myeloma (version 4.2024). Accessed May 7, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"bibr5-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"bibr6-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1717464"},{"key":"bibr7-10600280241271192","unstructured":"Biorender. Adapted from \u201cimmune therapy in multiple myeloma.\u201d Biorender. Published 2024. https:\/\/app.biorender.com\/biorender-templates"},{"key":"bibr8-10600280241271192","unstructured":"Abecma (Idecabtagene Vicleucel) [Prescribing Information]. Celgene Corporation; 2024."},{"key":"bibr9-10600280241271192","unstructured":"Carvykti (Ciltacabtagene Autoleucel) [Prescribing Information]. Janssen Biotech, Inc; 2024."},{"key":"bibr10-10600280241271192","unstructured":"Tecvayli (Teclistamab-cqyv) [Prescribing Information]. Janssen Biotech, Inc; 2024."},{"key":"bibr11-10600280241271192","unstructured":"FDA announcement. Accessed May 8, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approvals-talvey-talquetamab-tgvs-relapsed-or-refractory-multiple#:~:text=On%20August%2014%2C%202023%2C%20the,including%20a%20proteasome%20inhibitor%2C%20an"},{"key":"bibr12-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-05542-8"},{"key":"bibr13-10600280241271192","unstructured":"Talvey (Talquetamab-tgvs) [Prescribing Information]. Janssen Biotech, Inc; 2023."},{"key":"bibr14-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x"},{"key":"bibr15-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342"},{"key":"bibr16-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"bibr17-10600280241271192","doi-asserted-by":"publisher","DOI":"10.3390\/antib8030041"},{"key":"bibr18-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001"},{"key":"bibr19-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-446146"},{"key":"bibr20-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"bibr21-10600280241271192","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00636"},{"key":"bibr22-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"bibr23-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9"},{"key":"bibr24-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"bibr25-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"bibr26-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707"},{"key":"bibr27-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"bibr28-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967676.59550.94"},{"key":"bibr29-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187242"},{"key":"bibr30-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967680.90062.ca"},{"key":"bibr31-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr32-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"bibr33-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992"},{"key":"bibr34-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"bibr35-10600280241271192","unstructured":"Actemra (Tocilizumab) [Prescribing Information]. Genentech, Inc; 2022."},{"key":"bibr36-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"bibr37-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"bibr38-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"bibr39-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611750"},{"key":"bibr40-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004017"},{"key":"bibr41-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"bibr42-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"bibr43-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"bibr44-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"bibr45-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153817"},{"key":"bibr46-10600280241271192","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"bibr47-10600280241271192","unstructured":"IBM Corporation. IBM micromedex\u00ae. Accessed May 1, 2024. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/51E01A\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/404BFD\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.FindRedBook?navitem=topRedBook&isToolPage=true"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241271192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241271192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241271192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:47Z","timestamp":1777374827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241271192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10600280241271192"],"URL":"https:\/\/doi.org\/10.1177\/10600280241271192","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}